Abstract:(1) Background: The use of uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonists results in neuroprotective benefits in patients with moderate to severe Alzheimer’s disease. In this study, we demonstrated mathematical and computer modelling of the excitotoxicity phenomenon and performed virtual memantine therapy. (2) Methods: A computer simulation environment of the N-methyl-D-aspartate receptor combining biological mechanisms of channel activation by means of excessive extracellular glutamic acid concentration in three models of excitotoxicity severity. The simulation model is based on sliding register tables, where each table is associated with corresponding synaptic inputs. Modelling of the increase in extracellular glutamate concentration, through over-stimulation of NMDA receptors and exacerbation of excitotoxicity, is performed by gradually increasing the parameters of phenomenological events by the power function. Pathological models were virtually treated with 3–30 μM doses of memantine compared to controls. (3) Results: The virtual therapy results of memantine at doses of 3–30 μM in the pathological models of excitotoxicity severity show statistically significant neuroprotective benefits in AD patients with moderate severity, 1.25 (95% CI, 1.18–1.32) vs. 1.76 (95% CI, 1.71–1.80) vs. 1.53 (95% CI, 1.48–1.59), (p < 0.001), to severe, 1.32 (95% CI, 1.12–1.53) vs. 1.77 (95% CI, 1.72–1.82) vs. 1.73 (95% CI, 1.68–1.79), (p < 0.001), in the area of effects on memory. A statistically significant benefit of memantine was demonstrated for all neuronal parameters in pathological models. In the mild severity model, a statistically significant increase in frequency was obtained relative to virtual memantine treatment with a dose of 3 μM, which was 23.5 Hz (95% CI, 15.5–28.4) vs. 38.8 Hz (95% CI, 34.0–43.6), (p < 0.0001). In the intermediate excitotoxicity severity model, a statistically significant increase in frequency was obtained relative to virtual memantine therapy with a 3 μM dose of 26.0 Hz (95% CI, 15.7–36.2) vs. 39.0 Hz (95% CI, 34.2–43.8) and a 10 μM dose of 26.0 Hz (95% CI, 15.7–36.2) vs. 30.9 Hz (95% CI, 26.4–35.4), (p < 0.0001). A statistically significant increase in frequency was obtained in the advanced excitotoxicity severity model as in the medium. (4) Conclusions: The NMDA antagonist memantine causes neuroprotective benefits in patients with moderate to severe AD. One of the most important benefits of memantine is the improvement of cognitive function and beneficial effects on memory. On the other hand, memantine provides only symptomatic and temporary support for AD patients. Memantine is prescribed in the US and Europe if a patient has moderate to severe AD. Memantine has also been approved for mild to moderate AD patients. However, its very modest effect provides motivation for further research into new drugs in AD. We are the first to present a mathematical model of the NMDA receptor that allows the simulation of excitotoxicity and virtual memantine therapy.

Memantine Attenuates the Impairment of Spatial Learning and Memory of Pentylenetetrazol-Kindled Rats

Memantine Improves Spatial Learning And Memory Of Pentylenetetrazole-Kindled Rats With Increasing Arc/Arg3.1 And Camkii Alpha Expression

P4‐305: Withdrawn

A Randomized Controlled Trial Measuring Changes in Cerebral Blood Flow after Levetiracetam in Patients with Alzheimer’s Disease

Mechanisms of Histamine Ameliorating Memory Impairment Induced by Pentylenetetrazole-Kindling Epilepsy in Rats

Effects of Thioperamide on Seizure Development and Memory Impairment Induced by Pentylenetetrazole-Kindling Epilepsy in Rats.

Memantine Ameliorates Tau Protein Deposition and Secondary Damage in the Ipsilateral Thalamus and Sensory Decline Following Focal Cortical Infarction in Rats

Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats

Memantine Improves Cognitive Function and Alters Hippocampal and Cortical Proteome in Triple Transgenic Mouse Model of Alzheimer's Disease

Adenosine A1 Receptors Play an Important Protective Role Against Cognitive Impairment and Long-Term Potentiation Inhibition in a Pentylenetetrazol Mouse Model of Epilepsy.

Influence of chronic epilepsy on spatial memory retrieval in rats

Memantine induces manic episode in a 73-year-old patient with vascular neurocognitive disorder: a case report.

Decreased Synapse‐associated Proteins Are Associated with the Onset of Epileptic Memory Impairment in Endothelial CDK5‐deficient Mice

Effects of Memantine on Clinical Ratings, Fluorodeoxyglucose Positron Emission Tomography Measurements, and Cerebrospinal Fluid Assays in Patients with Moderate to Severe Alzheimer Dementia A 24-Week, Randomized, Clinical Trial

Effect of tetramethylpyrazine on function of spatial learning and memory in rat after focal cerebral ischemia

Effect of spatial learning capacity and emotional behavior on kindled rats by pentylenetetrazole

Multifunctional Memantine Nitrate Significantly Protects Against Glutamate-Induced Excitotoxicity Via Inhibiting Calcium Influx and Attenuating PI3K/Akt/GSK3beta Pathway

Ketogenic Diet Attenuates Spatial and Item Memory Impairment in Pentylenetetrazol-Kindled Rats

The Computer Simulation of Therapy with the NMDA Antagonist in Excitotoxic Neurodegeneration in an Alzheimer’s Disease-like Pathology

N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.

The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence